Home > Newsletters > Washington Drug Letter > High Court Could Review Preemption As Mutual Pharma Petitions
Washington Drug Letter
Aug. 13, 2012 | Vol. 44 No. 32
High Court Could Review Preemption As Mutual Pharma Petitions
Generic preemption issues may again wind up before the Supreme Court as generic maker Mutual Pharmaceutical is calling on it to reverse an appeals court decision that upheld a $21 million jury award to a patient injured by Mutual’s sulindac.
PhRMA Joins Generic Makers in Calling for SCOTUS Reversal of Mutual Decision Alabama High Court: Brand Pharmas Can Be Liable for Generics’ LabelingAlabama Supreme Court: Brand Drugmakers Can Be Held Liable for Generic-Drug LabelingAppeals Court: Pharma Off-Label Promotion Protected By First Amendment
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.